Pulmonary Embolism — Pretest Probability + D-dimer + Imaging

Pulmonary embolism presents across a wide spectrum — from incidental subsegmental PE found on imaging obtained for another reason, to sudden cardiovascular collapse from massive PE. The classic triad of pleuritic chest pain, dyspnea, and hemoptysis occurs in fewer than 20% of patients. Most patients present with dyspnea alone, or dyspnea with pleuritic chest pain.

Common presentations: sudden-onset dyspnea (the most common symptom), pleuritic chest pain (suggests peripheral infarction), tachycardia, hypoxemia, and syncope or presyncope (suggests massive or submassive PE with hemodynamic compromise). Cough and low-grade fever can occur with pulmonary infarction and may mimic pneumonia.

Risk factors: recent surgery or immobility (particularly orthopedic surgery), active malignancy, prior DVT or PE, pregnancy or postpartum state, oral contraceptives or hormone therapy, long-distance travel, and inherited thrombophilia. The absence of risk factors does not exclude PE — approximately 25–30% of PE occurs without an identifiable provoking factor.

Physical exam findings: tachycardia is the most common abnormal vital sign. Tachypnea, low-grade fever, and hypoxemia are common. Signs of right heart strain — elevated JVP, right ventricular heave, loud P2, right-sided S3 — suggest hemodynamically significant PE. Unilateral leg swelling, warmth, or tenderness suggests concurrent DVT (present in approximately 30–50% of PE cases).

ECG findings: sinus tachycardia is the most common finding. The classic S1Q3T3 pattern (S wave in lead I, Q wave and T-wave inversion in lead III) is specific but insensitive — present in only 10–15% of PE cases. Right bundle branch block, right axis deviation, and T-wave inversions in V1–V4 suggest right heart strain from significant PE.

The diagnostic workup for pulmonary embolism must begin with pretest probability assessment — before ordering D-dimer or imaging. Skipping this step leads to inappropriate D-dimer use in high-probability patients (where a positive result adds nothing) and inappropriate CT pulmonary angiography in low-probability patients (where a negative D-dimer would have been sufficient).

The Wells PE score is the most widely validated pretest probability tool. It assigns points for: clinical signs and symptoms of DVT (3 points), PE is the most likely diagnosis (3 points), heart rate above 100 (1.5 points), immobilization or surgery in the past 4 weeks (1.5 points), prior DVT or PE (1.5 points), hemoptysis (1 point), and malignancy (1 point). A score of 0–1 is low probability, 2–6 is moderate probability, and above 6 is high probability.

The PERC rule (Pulmonary Embolism Rule-out Criteria) can be applied to patients with low pretest probability to determine whether D-dimer testing is even necessary. If all 8 PERC criteria are met (age below 50, heart rate below 100, SpO2 above 94%, no unilateral leg swelling, no hemoptysis, no recent surgery or trauma, no prior DVT/PE, no exogenous estrogen), the probability of PE is below 2% and D-dimer testing can be safely omitted.

The clinical gestalt — the clinician's overall impression of whether PE is likely — is also a valid pretest probability assessment when used by experienced clinicians. However, structured tools like Wells reduce variability and are preferred in most settings.

D-dimer is a fibrin degradation product released when a clot is broken down. A negative D-dimer (below the age-adjusted threshold) in a low-to-moderate pretest probability patient effectively excludes PE — the negative predictive value is above 99%. This is the clinical value of D-dimer: it is a rule-out test.

A positive D-dimer is non-specific. D-dimer is elevated in infection, malignancy, pregnancy, recent surgery, trauma, atrial fibrillation, heart failure, liver disease, and many other conditions. A positive D-dimer in a patient with any of these conditions does not diagnose PE — it only indicates that imaging is needed. In high-probability patients, D-dimer is not useful at all — imaging is needed regardless of the D-dimer result.

Age-adjusted D-dimer thresholds improve specificity in older patients. The standard threshold (500 ng/mL) has very low specificity in patients above age 60 because D-dimer rises with age. The age-adjusted threshold (age × 10 ng/mL for patients above 50) maintains sensitivity while improving specificity — reducing unnecessary CT scans in older patients with low pretest probability.

The YEARS algorithm is an alternative approach that uses three clinical criteria (clinical signs of DVT, hemoptysis, PE as the most likely diagnosis) combined with D-dimer to determine whether CT is needed. In patients with no YEARS criteria and D-dimer below 1000 ng/mL, or in patients with one or more YEARS criteria and D-dimer below 500 ng/mL, PE can be excluded without CT.

CT pulmonary angiography (CTPA) is the definitive diagnostic test for PE. It has a sensitivity of approximately 83% and specificity of 96% for PE. It also provides information about right heart strain, alternative diagnoses, and the extent of clot burden.

CTPA is indicated when: pretest probability is high (regardless of D-dimer), pretest probability is low-to-moderate and D-dimer is positive, or D-dimer cannot be reliably interpreted (pregnancy, malignancy, recent surgery). It should not be ordered in low-probability patients with a negative D-dimer — the pre-test probability is already below 2% and CT adds radiation exposure without diagnostic benefit.

Subsegmental PE — clot limited to subsegmental pulmonary arteries — is increasingly detected with modern high-resolution CT. The clinical significance of isolated subsegmental PE is uncertain, and anticoagulation decisions in this setting should be individualized based on symptoms, cardiopulmonary reserve, and bleeding risk.

V/Q scanning is an alternative when CTPA is contraindicated (severe contrast allergy, renal failure). A normal V/Q scan excludes PE with high confidence. A high-probability V/Q scan in a high-pretest-probability patient confirms PE. Intermediate or indeterminate V/Q scans require additional evaluation.

Risk stratification determines the urgency and intensity of treatment. PE is classified as massive, submassive (intermediate-risk), or low-risk based on hemodynamic status and markers of right heart strain.

Massive PE is defined by hemodynamic instability: sustained systolic BP below 90 mmHg, or a drop of 40 mmHg from baseline for more than 15 minutes, not explained by other causes. Massive PE carries a mortality of 30–50% and requires immediate systemic thrombolysis (if no contraindications) or surgical embolectomy.

Submassive PE (intermediate-risk) is hemodynamically stable but has evidence of right heart strain: right ventricular dysfunction on echocardiography or CT (RV/LV ratio above 0.9), elevated troponin, or elevated BNP/NT-proBNP. Submassive PE carries a mortality of 3–15%. Anticoagulation is the standard treatment; systemic thrombolysis is not routinely recommended due to bleeding risk but may be considered for patients who deteriorate. Catheter-directed thrombolysis is an option at experienced centers.

Low-risk PE is hemodynamically stable without right heart strain markers. Anticoagulation is the treatment. Many low-risk PE patients can be managed as outpatients — the Hestia criteria and PESI score identify patients safe for outpatient treatment.

Anticoagulation is the cornerstone of PE treatment for all patients who are not in massive PE requiring thrombolysis. The goal is to prevent clot propagation and allow endogenous fibrinolysis to resolve the existing clot.

DOACs (apixaban, rivaroxaban) are the preferred agents for most patients with PE — they are at least as effective as warfarin with lower bleeding risk, no INR monitoring required, and more predictable pharmacokinetics. Rivaroxaban and apixaban have approved dosing regimens that do not require initial parenteral anticoagulation (rivaroxaban 15 mg twice daily for 21 days, then 20 mg daily; apixaban 10 mg twice daily for 7 days, then 5 mg twice daily). LMWH followed by warfarin is the preferred regimen for malignancy-associated PE (LMWH) or when DOACs are contraindicated.

Duration of anticoagulation depends on whether the PE was provoked or unprovoked. Provoked PE (associated with a transient, reversible risk factor — major surgery, immobility, estrogen use, trauma) is treated with 3 months of anticoagulation. Unprovoked PE carries a recurrence risk of approximately 10% per year after stopping anticoagulation and typically warrants extended therapy. The decision to extend should weigh the recurrence risk against the bleeding risk of continued anticoagulation.

Malignancy-associated PE is treated with anticoagulation for as long as the cancer is active. LMWH was historically preferred, but DOACs (apixaban, rivaroxaban, edoxaban) are now recommended as alternatives for most cancer-associated PE — with the exception of GI and genitourinary malignancies, where the higher GI bleeding risk with DOACs may favor LMWH.

Recurrent PE on anticoagulation is uncommon but should be considered when a patient on therapeutic anticoagulation develops new or worsening symptoms. Before diagnosing recurrent PE, confirm that the patient is actually taking the anticoagulant and that the dose is appropriate. Subtherapeutic anticoagulation (missed doses, drug interactions, inadequate dosing) is the most common reason for apparent treatment failure.

True recurrent PE on therapeutic anticoagulation warrants evaluation for heparin-induced thrombocytopenia (if on heparin), antiphospholipid syndrome, occult malignancy, and inherited thrombophilia. Switching anticoagulant class (e.g., from DOAC to LMWH) or escalating to a higher dose may be appropriate depending on the clinical context.

Post-PE syndrome: a subset of patients develop persistent dyspnea, exercise intolerance, and reduced quality of life after PE — even after adequate anticoagulation. This may represent incomplete clot resolution, right ventricular dysfunction, or deconditioning. Echocardiography at 3–6 months after PE is appropriate to assess for residual right heart dysfunction.

Chronic thromboembolic pulmonary hypertension (CTEPH): approximately 2–4% of patients with PE develop CTEPH — persistent pulmonary hypertension from organized, non-resolving thrombus in the pulmonary vasculature. It presents as progressive dyspnea and exercise intolerance months to years after the initial PE. V/Q scan is the preferred screening test (more sensitive than CTPA for CTEPH). Pulmonary endarterectomy is potentially curative for surgically accessible disease. Referral to a CTEPH center is appropriate for any patient with suspected CTEPH.